John Renger

John Renger is the current Chief Scientific Officer at Cerevel Therapeutics. John has also previously served as the VP, Head of R&D and Regulatory Affairs at Imbrium Therapeutics from April 2018 to April 2019. In this role, they were responsible for leading teams overseeing discovery of neurosymptomatic treatments for Alzheimer's, Parkinson's, and Psychiatric Diseases, as well as for Site Leadership at West Point, PA. Prior to this, Renger served as the Head of Clinical Research and Translational Medicine at Purdue Pharma L.P. from August 2016 to April 2018. In this role, they were responsible for the company's clinical research and translation medicine efforts.

Renger began their career as a Staff Scientist at the Brain Science Institute, RIKEN in November 1997. In this role, they were responsible for demonstrating novel physiological development of presynaptic glutamatergic transmission with unique technological approaches. John was also responsible for creating novel research tools and models to understand development of glutamatergic neural plasticity. In May 1999, they transitioned to a role as a Postdoctoral Fellow at the Massachusetts Institute of Technology. In this role, they continued their work in understanding physiological development of presynaptic glutamatergic transmission. John also took on additional responsibility for overseeing the creation of new research tools and models related to neural plasticity.

In October 2001, Renger transitioned to a role as Associate Vice President at Merck. In this role, they were responsible for drug target acceleration and translational capabilities related to the company's neuroscience portfolio. John remained in this role until August 2016 when they transitioned to their current role as Chief Scientific Officer at Cerevel Therapeutics.

John Renger received a Ph. D. in Biological Sciences / Neurogenetics from the University of Iowa, and a B. S. in Biology from the University of Iowa.

Some of their coworkers include Raymond Sanchez - Chief Medical Officer, Kathleen Tregoning - Chief Corporate Affairs Officer, and Abraham N. Ceesay - President. John Renger reports to Tony Coles, CEO & Chairperson.